Plasmodium vivax vaccine research – we've only just begun

International Journal for Parasitology

Volumn 47, Issue 2-3, 2017, Pages 111-118

  Tham, Wai Hong ^a,b   Beeson, James G ^c,d   Rayner, Julian C ^e  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BURNET INSTITUTE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Erythrocyte invasion; Malaria; Plasmodium vivax; Vaccine

Indexed keywords

EPITOPE; MALARIA VACCINE; PARASITE ANTIGEN; PLASMODIUM VIVAX ANTIGEN; PLASMODIUM VIVAX VACCINE; PROTEIN RBP; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

BLOOD; DISEASE TRANSMISSION; DRUG DEVELOPMENT; MALARIA; PROTOZOAN; VACCINE;

ANTIBODY PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; HUMORAL IMMUNITY; MOLECULAR WEIGHT; NONHUMAN; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PROTEIN EXPRESSION; RETICULOCYTE; REVIEW; ANIMAL; HUMAN; IMMUNOLOGY; MALARIA, VIVAX; PARASITOLOGY;

AFRICA;

PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

ANIMALS; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; PLASMODIUM VIVAX;

EID: 85007571953     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2016.09.006     Document Type: Review

References (102)

1. Adams, J.H., Sim, B.K., Dolan, S.A., Fang, X., Kaslow, D.C., Miller, L.H., A family of erythrocyte binding proteins of malaria parasites. Proc. Natl. Acad. Sci. U.S.A. 89 (1992), 7085–7089.
2. Arevalo-Herrera, M., Lopez-Perez, M., Dotsey, E., Jain, A., Rubiano, K., Felgner, P.L., Davies, D.H., Herrera, S., Antibody profiling in naive and semi-immune individuals experimentally challenged with Plasmodium vivax sporozoites. PLoS Negl. Trop. Dis., 10, 2016, e0004563.
3. Arnott, A., Wapling, J., Mueller, I., Ramsland, P.A., Siba, P.M., Reeder, J.C., Barry, A.E., Distinct patterns of diversity, population structure and evolution in the AMA1 genes of sympatric Plasmodium falciparum and Plasmodium vivax populations of Papua New Guinea from an area of similarly high transmission. Malar. J., 13, 2014, 233.
4. Baird, J.K., Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 26 (2013), 36–57.
5. Baird, K.J., Maguire, J.D., Price, R.N., Diagnosis and treatment of Plasmodium vivax malaria. Adv. Parasitol. 80 (2012), 203–270.
6. Barry, A.E., Beeson, J.G., Reeder, J.C., Fowkes, F.J., Arnott, A., Using population genetics to guide malaria vaccine design. Okwa, O., (eds.) Malaria Parasites, 2012, In Tech, 10.5772/34031.
7. Batchelor, J.D., Zahm, J.A., Tolia, N.H., Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC. Nat. Struct. Mol. Biol. 18 (2011), 908–914.
8. Batchelor, J.D., Malpede, B.M., Omattage, N.S., DeKoster, G.T., Henzler-Wildman, K.A., Tolia, N.H., Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLoS Pathog., 10, 2014, e1003869.
9. Beeson, J.G., Osier, F.H., Engwerda, C.R., Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 24 (2008), 578–584.
10. Beeson, J.G., Drew, D.R., Boyle, M.J., Feng, G., Fowkes, F.J., Richards, J.S., Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiol. Rev. 40 (2016), 343–372.
11. Bennett, J.W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L.A., McCarthy, W.F., Cowden, J.J., Regules, J., Spring, M.D., Paolino, K., Hartzell, J.D., Cummings, J.F., Richie, T.L., Lumsden, J., Kamau, E., Murphy, J., Lee, C., Parekh, F., Birkett, A., Cohen, J., Ballou, W.R., Polhemus, M.E., Vanloubbeeck, Y.F., Vekemans, J., Ockenhouse, C.F., Phase 1/2a trial of Plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy. PLoS Negl. Trop. Dis., 10, 2016, e0004423.
12. Bergmann-Leitner, E.S., Duncan, E.H., Mullen, G.E., Burge, J.R., Khan, F., Long, C.A., Angov, E., Lyon, J.A., Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am. J. Trop. Med. Hyg. 75 (2006), 437–442.
13. Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T., Druilhe, P., Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172 (1990), 1633–1641.
14. Boyle, M., Reiling, L., Feng, G., Langer, C., Osier, F., Aspeling-Jones, H., Cheng, Y., Stubbs, J., Tetteh, K., Conway, D., McCarthy, J., Muller, I., Marsh, K., Anders, R., Beeson, J., Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against clinical malaria. Immunity 42 (2015), 580–590.
15. Bozdech, Z., Mok, S., Hu, G., Imwong, M., Jaidee, A., Russell, B., Ginsburg, H., Nosten, F., Day, N.P., White, N.J., Carlton, J.M., Preiser, P.R., The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 16290–16295.
16. Bustamante, L.Y., Bartholdson, S.J., Crosnier, C., Campos, M.G., Wanaguru, M., Nguon, C., Kwiatkowski, D.P., Wright, G.J., Rayner, J.C., A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 31 (2013), 373–379.
17. Carlton, J.M., Adams, J.H., Silva, J.C., Bidwell, S.L., Lorenzi, H., Caler, E., Crabtree, J., Angiuoli, S.V., Merino, E.F., Amedeo, P., Cheng, Q., Coulson, R.M., Crabb, B.S., Del Portillo, H.A., Essien, K., Feldblyum, T.V., Fernandez-Becerra, C., Gilson, P.R., Gueye, A.H., Guo, X., Kang'a, S., Kooij, T.W., Korsinczky, M., Meyer, E.V., Nene, V., Paulsen, I., White, O., Ralph, S.A., Ren, Q., Sargeant, T.J., Salzberg, S.L., Stoeckert, C.J., Sullivan, S.A., Yamamoto, M.M., Hoffman, S.L., Wortman, J.R., Gardner, M.J., Galinski, M.R., Barnwell, J.W., Fraser-Liggett, C.M., Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455 (2008), 757–763.
18. de Cassan, S.C., Shakri, A.R., Llewellyn, D., Elias, S.C., Cho, J.S., Goodman, A.L., Jin, J., Douglas, A.D., Suwanarusk, R., Nosten, F.H., Renia, L., Russell, B., Chitnis, C.E., Draper, S.J., Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax. Front. Immunol., 6, 2015, 348.
19. Chan, J.A., Fowkes, F.J., Beeson, J.G., Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cell. Mol. Life Sci. 71 (2014), 3633–3657.
20. Charnaud, S.C., McGready, R., Herten-Crabb, A., Powell, R., Guy, A., Langer, C., Richards, J.S., Gilson, P.R., Chotivanich, K., Tsuboi, T., Narum, D.L., Pimanpanarak, M., Simpson, J.A., Beeson, J.G., Nosten, F., Fowkes, F.J., Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting. Sci. Rep., 6, 2016, 20859.
21. Chen, J.H., Jung, J.W., Wang, Y., Ha, K.S., Lu, F., Lim, C.S., Takeo, S., Tsuboi, T., Han, E.T., Immunoproteomics profiling of blood stage Plasmodium vivax infection by high-throughput screening assays. J. Proteome Res. 9 (2010), 6479–6489.
22. Chen, L., Xu, Y., Healer, J., Thompson, J.K., Smith, B.J., Lawrence, M.C., Cowman, A.F., Crystal structure of PfRh5, an essential P. falciparum ligand for invasion of human erythrocytes. eLife, 3, 2014.
23. Chen, E., Salinas, N.D., Ntumngia, F.B., Adams, J.H., Tolia, N.H., Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design. PLoS Negl. Trop. Dis., 9, 2015, e0003644.
24. Chen, E., Salinas, N.D., Huang, Y., Ntumngia, F., Plasencia, M.D., Gross, M.L., Adams, J.H., Tolia, N.H., Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 6277–6282.
25. Cheng, Y., Ito, D., Sattabongkot, J., Lim, C.S., Kong, D.H., Ha, K.S., Wang, B., Tsuboi, T., Han, E.T., Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population. Malar. J., 12, 2013, 323.
26. Chimma, P., Roussilhon, C., Sratongno, P., Ruangveerayuth, R., Pattanapanyasat, K., Perignon, J.L., Roberts, D.J., Druilhe, P., A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog., 5, 2009, e1000631.
27. Cho, J.S., Russell, B., Kosasaivee, V., Zhang, R., Colin, Y., Bertrand, O., Chandramohanadas, R., Chu, C.S., Nosten, F., Renia, L., Malleret, B., Unambiguous determination of Plasmodium vivax reticulocyte invasion by flow cytometry. Int. J. Parasitol. 46 (2016), 31–39.
28. Chootong, P., Ntumngia, F.B., VanBuskirk, K.M., Xainli, J., Cole-Tobian, J.L., Campbell, C.O., Fraser, T.S., King, C.L., Adams, J.H., Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect. Immun. 78 (2010), 1089–1095.
29. Chootong, P., Panichakul, T., Permmongkol, C., Barnes, S.J., Udomsangpetch, R., Adams, J.H., Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand. PLoS One, 7, 2012, e35769.
30. Chuquiyauri, R., Molina, D.M., Moss, E.L., Wang, R., Gardner, M.J., Brouwer, K.C., Torres, S., Gilman, R.H., Llanos-Cuentas, A., Neafsey, D.E., Felgner, P., Liang, X., Vinetz, J.M., Genome-scale protein microarray comparison of human antibody responses in Plasmodium vivax relapse and reinfection. Am. J. Trop. Med. Hyg. 93 (2015), 801–809.
31. Cohen, S., Mc, G.I., Carrington, S., Gamma-globulin and acquired immunity to human malaria. Nature 192 (1961), 733–737.
32. Cole-Tobian, J.L., Michon, P., Biasor, M., Richards, J.S., Beeson, J.G., Mueller, I., King, C.L., Strain-specific Duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children. Infect. Immun. 77 (2009), 4009–4017.
33. Collins, W.E., Jeffery, G.M., A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am. J. Trop. Med. Hyg. 61 (1999), 20–35.
34. Conway, D.J., Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet. 31 (2015), 97–107.
35. Crompton, P.D., Kayala, M.A., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G.E., Molina, D.M., Burk, C.R., Waisberg, M., Jasinskas, A., Tan, X., Doumbo, S., Doumtabe, D., Kone, Y., Narum, D.L., Liang, X., Doumbo, O.K., Miller, L.H., Doolan, D.L., Baldi, P., Felgner, P.L., Pierce, S.K., A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 6958–6963.
36. Crosnier, C., Bustamante, L.Y., Bartholdson, S.J., Bei, A.K., Theron, M., Uchikawa, M., Mboup, S., Ndir, O., Kwiatkowski, D.P., Duraisingh, M.T., Rayner, J.C., Wright, G.J., Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480 (2011), 534–537.
37. Crosnier, C., Wanaguru, M., McDade, B., Osier, F.H., Marsh, K., Rayner, J.C., Wright, G.J., A library of functional recombinant cell surface and secreted Plasmodium falciparum merozoite proteins. Mol. Cell. Proteomics 12 (2013), 3976–3986.
38. Cutts, J., Powell, R., Agius, P., Beeson, J., Simpson, J., Fowkes, F., Immunological markers of P. vivax exposure and immunity: a systematic review and meta-analysis. BMC Med., 12, 2014, 150.
39. Dent, A.E., Nakajima, R., Liang, L., Baum, E., Moormann, A.M., Sumba, P.O., Vulule, J., Babineau, D., Randall, A., Davies, D.H., Felgner, P.L., Kazura, J.W., Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. J. Infect. Dis. 212 (2015), 1429–1438.
40. Doolan, D.L., Mu, Y., Unal, B., Sundaresh, S., Hirst, S., Valdez, C., Randall, A., Molina, D., Liang, X., Freilich, D.A., Oloo, J.A., Blair, P.L., Aguiar, J.C., Baldi, P., Davies, D.H., Felgner, P.L., Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8 (2008), 4680–4694.
41. Douglas, A.D., Williams, A.R., Illingworth, J.J., Kamuyu, G., Biswas, S., Goodman, A.L., Wyllie, D.H., Crosnier, C., Miura, K., Wright, G.J., Long, C.A., Osier, F.H., Marsh, K., Turner, A.V., Hill, A.V., Draper, S.J., The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun., 2, 2011, 601.
42. Douglas, A.D., Williams, A.R., Knuepfer, E., Illingworth, J.J., Furze, J.M., Crosnier, C., Choudhary, P., Bustamante, L.Y., Zakutansky, S.E., Awuah, D.K., Alanine, D.G., Theron, M., Worth, A., Shimkets, R., Rayner, J.C., Holder, A.A., Wright, G.J., Draper, S.J., Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J. Immunol. 192 (2014), 245–258.
43. Douglas, A.D., Baldeviano, G.C., Lucas, C.M., Lugo-Roman, L.A., Crosnier, C., Bartholdson, S.J., Diouf, A., Miura, K., Lambert, L.E., Ventocilla, J.A., Leiva, K.P., Milne, K.H., Illingworth, J.J., Spencer, A.J., Hjerrild, K.A., Alanine, D.G., Turner, A.V., Moorhead, J.T., Edgel, K.A., Wu, Y., Long, C.A., Wright, G.J., Lescano, A.G., Draper, S.J., A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 17 (2015), 130–139.
44. Duncan, C.J., Hill, A.V., Ellis, R.D., Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. Hum. Vaccin. Immunother. 8 (2012), 706–714.
45. Franca, C.T., Hostetler, J.B., Sharma, S., White, M.T., Lin, E., Kiniboro, B., Waltmann, A., Darcy, A.W., Li Wai Suen, C.S., Siba, P., King, C.L., Rayner, J.C., Fairhurst, R.M., Mueller, I., An antibody screen of a Plasmodium vivax antigen library identifies novel merozoite proteins associated with clinical protection. PLoS Negl. Trop. Dis., 10, 2016, e0004639.
46. Galinski, M.R., Medina, C.C., Ingravallo, P., Barnwell, J.W., A reticulocyte-binding protein complex of Plasmodium vivax merozoites. Cell 69 (1992), 1213–1226.
47. Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A., Nelson, K.E., Bowman, S., Paulsen, I.T., James, K., Eisen, J.A., Rutherford, K., Salzberg, S.L., Craig, A., Kyes, S., Chan, M.S., Nene, V., Shallom, S.J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M.W., Vaidya, A.B., Martin, D.M., Fairlamb, A.H., Fraunholz, M.J., Roos, D.S., Ralph, S.A., McFadden, G.I., Cummings, L.M., Subramanian, G.M., Mungall, C., Venter, J.C., Carucci, D.J., Hoffman, S.L., Newbold, C., Davis, R.W., Fraser, C.M., Barrell, B., Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419 (2002), 498–511.
48. Gething, P.W., Elyazar, I.R., Moyes, C.L., Smith, D.L., Battle, K.E., Guerra, C.A., Patil, A.P., Tatem, A.J., Howes, R.E., Myers, M.F., George, D.B., Horby, P., Wertheim, H.F., Price, R.N., Mueller, I., Baird, J.K., Hay, S.I., A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl. Trop. Dis., 6, 2012, e1814.
49. Grimberg, B.T., Udomsangpetch, R., Xainli, J., McHenry, A., Panichakul, T., Sattabongkot, J., Cui, L., Bockarie, M., Chitnis, C., Adams, J., Zimmerman, P.A., King, C.L., Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med., 4, 2007, e337.
50. Grimberg, B.T., Udomsangpetch, R., Xainli, J., McHenry, A., Panichakul, T., Sattabongkot, J., Cui, L., Bockarie, M., Chitnis, C., Adams, J.H., Zimmerman, P.A., King, C.L., Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med., 4, 2007, e337.
51. Gruszczyk, J., Lim, N.T., Arnott, A., He, W.Q., Nguitragool, W., Roobsoong, W., Mok, Y.F., Murphy, J.M., Smith, K.R., Lee, S., Bahlo, M., Mueller, I., Barry, A.E., Tham, W.H., Structurally conserved erythrocyte-binding domain in Plasmodium provides a versatile scaffold for alternate receptor engagement. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), E191–E200.
52. Han, J.H., Li, J., Wang, B., Lee, S.K., Nyunt, M.H., Na, S., Park, J.H., Han, E.T., Identification of immunodominant B-cell epitope regions of reticulocyte binding proteins in Plasmodium vivax by protein microarray based immunoscreening. Korean J. Parasitol. 53 (2015), 403–411.
53. Hayton, K., Gaur, D., Liu, A., Takahashi, J., Henschen, B., Singh, S., Lambert, L., Furuya, T., Bouttenot, R., Doll, M., Nawaz, F., Mu, J., Jiang, L., Miller, L.H., Wellems, T.E., Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4 (2008), 40–51.
54. Hester, J., Chan, E.R., Menard, D., Mercereau-Puijalon, O., Barnwell, J., Zimmerman, P.A., Serre, D., De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes. PLoS Negl. Trop. Dis., 7, 2013, e2569.
55. Hietanen, J., Chim-Ong, A., Chiramanewong, T., Gruszczyk, J., Roobsoong, W., Tham, W.H., Sattabongkot, J., Nguitragool, W., Gene models, expression repertoire, and immune response of Plasmodium vivax reticulocyte binding proteins. Infect. Immun. 84 (2015), 677–685.
56. Hill, D.L., Eriksson, E.M., Li Wai Suen, C.S., Chiu, C.Y., Ryg-Cornejo, V., Robinson, L.J., Siba, P.M., Mueller, I., Hansen, D.S., Schofield, L., Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One, 8, 2013, e74627.
57. Hostetler, J.B., Sharma, S., Bartholdson, S.J., Wright, G.J., Fairhurst, R.M., Rayner, J.C., A library of Plasmodium vivax recombinant merozoite proteins reveals new vaccine candidates and protein–protein interactions. PLoS Negl. Trop. Dis., 9, 2015, e0004264.
58. Hupalo, D.N., Luo, Z., Melnikov, A., Sutton, P.L., Rogov, P., Escalante, A., Vallejo, A.F., Herrera, S., Arevalo-Herrera, M., Fan, Q., Wang, Y., Cui, L., Lucas, C.M., Durand, S., Sanchez, J.F., Baldeviano, G.C., Lescano, A.G., Laman, M., Barnadas, C., Barry, A., Mueller, I., Kazura, J.W., Eapen, A., Kanagaraj, D., Valecha, N., Ferreira, M.U., Roobsoong, W., Nguitragool, W., Sattabonkot, J., Gamboa, D., Kosek, M., Vinetz, J.M., Gonzalez-Ceron, L., Birren, B.W., Neafsey, D.E., Carlton, J.M., Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nat. Genet. 48 (2016), 953–958.
59. Irani, V., Ramsland, P.A., Guy, A.J., Siba, P.M., Mueller, I., Richards, J.S., Beeson, J.G., Acquisition of functional antibodies that block the binding of erythrocyte-binding antigen 175 and protection against Plasmodium falciparum malaria in children. Clin. Infect. Dis. 61 (2015), 1244–1252.
60. Joos, C., Marrama, L., Polson, H.E., Corre, S., Diatta, A.M., Diouf, B., Trape, J.F., Tall, A., Longacre, S., Perraut, R., Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One, 5, 2010, e9871.
61. Joyner, C., Barnwell, J.W., Galinski, M.R., No more monkeying around: primate malaria model systems are key to understanding Plasmodium vivax liver-stage biology, hypnozoites, and relapses. Front. Microbiol., 6, 2015, 145.
62. Kennedy, A.T., Schmidt, C.Q., Thompson, J.K., Weiss, G.E., Taechalertpaisarn, T., Gilson, P.R., Barlow, P.N., Crabb, B.S., Cowman, A.F., Tham, W.H., Recruitment of factor H as a novel complement evasion strategy for blood-stage Plasmodium falciparum infection. J. Immunol. 196 (2016), 1239–1248.
63. King, C.L., Michon, P., Shakri, A.R., Marcotty, A., Stanisic, D., Zimmerman, P.A., Cole-Tobian, J.L., Mueller, I., Chitnis, C.E., Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl. Acad. Sci. U.S.A. 105 (2008), 8363–8368.
64. Langhorne, J., Ndungu, F.M., Sponaas, A.M., Marsh, K., Immunity to malaria: more questions than answers. Nat. Immunol. 9 (2008), 725–732.
65. Liu, W., Li, Y., Learn, G.H., Rudicell, R.S., Robertson, J.D., Keele, B.F., Ndjango, J.B., Sanz, C.M., Morgan, D.B., Locatelli, S., Gonder, M.K., Kranzusch, P.J., Walsh, P.D., Delaporte, E., Mpoudi-Ngole, E., Georgiev, A.V., Muller, M.N., Shaw, G.M., Peeters, M., Sharp, P.M., Rayner, J.C., Hahn, B.H., Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature 467 (2010), 420–425.
66. Liu, W., Li, Y., Shaw, K.S., Learn, G.H., Plenderleith, L.J., Malenke, J.A., Sundararaman, S.A., Ramirez, M.A., Crystal, P.A., Smith, A.G., Bibollet-Ruche, F., Ayouba, A., Locatelli, S., Esteban, A., Mouacha, F., Guichet, E., Butel, C., Ahuka-Mundeke, S., Inogwabini, B.I., Ndjango, J.B., Speede, S., Sanz, C.M., Morgan, D.B., Gonder, M.K., Kranzusch, P.J., Walsh, P.D., Georgiev, A.V., Muller, M.N., Piel, A.K., Stewart, F.A., Wilson, M.L., Pusey, A.E., Cui, L., Wang, Z., Farnert, A., Sutherland, C.J., Nolder, D., Hart, J.A., Hart, T.B., Bertolani, P., Gillis, A., LeBreton, M., Tafon, B., Kiyang, J., Djoko, C.F., Schneider, B.S., Wolfe, N.D., Mpoudi-Ngole, E., Delaporte, E., Carter, R., Culleton, R.L., Shaw, G.M., Rayner, J.C., Peeters, M., Hahn, B.H., Sharp, P.M., African origin of the malaria parasite Plasmodium vivax. Nat. Commun., 5, 2014, 3346.
67. Malkin, E.M., Durbin, A.P., Diemert, D.J., Sattabongkot, J., Wu, Y., Miura, K., Long, C.A., Lambert, L., Miles, A.P., Wang, J., Stowers, A., Miller, L.H., Saul, A., Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 (2005), 3131–3138.
68. Malleret, B., Li, A., Zhang, R., Tan, K.S., Suwanarusk, R., Claser, C., Cho, J.S., Koh, E.G., Chu, C.S., Pukrittayakamee, S., Ng, M.L., Ginhoux, F., Ng, L.G., Lim, C.T., Nosten, F., Snounou, G., Renia, L., Russell, B., Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes. Blood 125 (2015), 1314–1324.
69. Mamillapalli, A., Pattnaik, P., Sharma, M., Sharma, S.K., Tyagi, P.K., Joshi, H., Chitnis, C.E., Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175: implications for malaria vaccine development. Mol. Biochem. Parasitol. 146 (2006), 120–123.
70. McCallum, F.J., Persson, K.E., Mugyenyi, C.K., Fowkes, F.J., Simpson, J.A., Richards, J.S., Williams, T.N., Marsh, K., Beeson, J.G., Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One, 3, 2008, e3571.
71. McIntosh, R.S., Shi, J., Jennings, R.M., Chappel, J.C., de Koning-Ward, T.F., Smith, T., Green, J., van Egmond, M., Leusen, J.H., Lazarou, M., van de Winkel, J., Jones, T.S., Crabb, B.S., Holder, A.A., Pleass, R.J., The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog., 3, 2007, e72.
72. Menard, D., Barnadas, C., Bouchier, C., Henry-Halldin, C., Gray, L.R., Ratsimbasoa, A., Thonier, V., Carod, J.F., Domarle, O., Colin, Y., Bertrand, O., Picot, J., King, C.L., Grimberg, B.T., Mercereau-Puijalon, O., Zimmerman, P.A., Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 5967–5971.
73. Mikolajczak, S.A., Vaughan, A.M., Kangwanrangsan, N., Roobsoong, W., Fishbaugher, M., Yimamnuaychok, N., Rezakhani, N., Lakshmanan, V., Singh, N., Kaushansky, A., Camargo, N., Baldwin, M., Lindner, S.E., Adams, J.H., Sattabongkot, J., Kappe, S.H., Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe 17 (2015), 526–535.
74. Miura, K., Takashima, E., Deng, B., Tullo, G., Diouf, A., Moretz, S.E., Nikolaeva, D., Diakite, M., Fairhurst, R.M., Fay, M.P., Long, C.A., Tsuboi, T., Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Infect. Immun. 81 (2013), 4377–4382.
75. Mueller, I., Galinski, M.R., Baird, J.K., Carlton, J.M., Kochar, D.K., Alonso, P.L., del Portillo, H.A., Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 9 (2009), 555–566.
76. Mueller, I., Shakri, A.R., Chitnis, C.E., Development of vaccines for Plasmodium vivax malaria. Vaccine 33 (2015), 7489–7495.
77. Neafsey, D.E., Galinsky, K., Jiang, R.H., Young, L., Sykes, S.M., Saif, S., Gujja, S., Goldberg, J.M., Young, S., Zeng, Q., Chapman, S.B., Dash, A.P., Anvikar, A.R., Sutton, P.L., Birren, B.W., Escalante, A.A., Barnwell, J.W., Carlton, J.M., The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat. Genet. 44 (2012), 1046–1050.
78. Nogueira, P.A., Alves, F.P., Fernandez-Becerra, C., Pein, O., Santos, N.R., Pereira da Silva, L.H., Camargo, E.P., del Portillo, H.A., A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect. Immun. 74 (2006), 2726–2733.
79. Ntumngia, F.B., Adams, J.H., Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax Duffy binding protein. Clin. Vaccine Immunol. 19 (2012), 30–36.
80. Osier, F.H., Feng, G., Boyle, M.J., Langer, C., Zhou, J., Richards, J.S., McCallum, F.J., Reiling, L., Jaworowski, A., Anders, R.F., Marsh, K., Beeson, J.G., Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med., 12, 2014, 108.
81. Osier, F.H., Mackinnon, M.J., Crosnier, C., Fegan, G., Kamuyu, G., Wanaguru, M., Ogada, E., McDade, B., Rayner, J.C., Wright, G.J., Marsh, K., New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl. Med., 6, 2014, 247ra102.
82. Pearson, R.D., Amato, R., Auburn, S., Miotto, O., Almagro-Garcia, J., Amaratunga, C., Suon, S., Mao, S., Noviyanti, R., Trimarsanto, H., Marfurt, J., Anstey, N.M., William, T., Boni, M.F., Dolecek, C., Tran, H.T., White, N.J., Michon, P., Siba, P., Tavul, L., Harrison, G., Barry, A., Mueller, I., Ferreira, M.U., Karunaweera, N., Randrianarivelojosia, M., Gao, Q., Hubbart, C., Hart, L., Jeffery, B., Drury, E., Mead, D., Kekre, M., Campino, S., Manske, M., Cornelius, V.J., MacInnis, B., Rockett, K.A., Miles, A., Rayner, J.C., Fairhurst, R.M., Nosten, F., Price, R.N., Kwiatkowski, D.P., Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nat. Genet. 48 (2016), 959–964.
83. Persson, K.E., Lee, C.T., Marsh, K., Beeson, J.G., Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J. Clin. Microbiol. 44 (2006), 1665–1673.
84. Persson, K.E., McCallum, F.J., Reiling, L., Lister, N.A., Stubbs, J., Cowman, A.F., Marsh, K., Beeson, J.G., Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin. Invest. 118 (2008), 342–351.
85. Richards, J.S., Arumugam, T.U., Reiling, L., Healer, J., Hodder, A.N., Fowkes, F.J., Cross, N., Langer, C., Takeo, S., Uboldi, A.D., Thompson, J.K., Gilson, P.R., Coppel, R.L., Siba, P.M., King, C.L., Torii, M., Chitnis, C.E., Narum, D.L., Mueller, I., Crabb, B.S., Cowman, A.F., Tsuboi, T., Beeson, J.G., Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J. Immunol. 191 (2013), 795–809.
86. Roobsoong, W., The in vitro invasion inhibition assay (IIA) for Plasmodium vivax. Methods Mol. Biol. 1325 (2015), 187–196.
87. Rosa, T.F., Flammersfeld, A., Ngwa, C.J., Kiesow, M., Fischer, R., Zipfel, P.F., Skerka, C., Pradel, G., The Plasmodium falciparum blood stages acquire factor H family proteins to evade destruction by human complement. Cell. Microbiol. 18 (2016), 573–590.
88. RTS, Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386 (2015), 31–45.
89. Souza-Silva, F.A., da Silva-Nunes, M., Sanchez, B.A., Ceravolo, I.P., Malafronte, R.S., Brito, C.F., Ferreira, M.U., Carvalho, L.H., Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon. Am. J. Trop. Med. Hyg. 82 (2010), 185–193.
90. Srivastava, A., Durocher, Y., Gamain, B., Expressing full-length functional PfEMP1 proteins in the HEK293 expression system. Methods Mol. Biol. 923 (2013), 307–319.
91. Stanisic, D.I., Javati, S., Kiniboro, B., Lin, E., Jiang, J., Singh, B., Meyer, E.V., Siba, P., Koepfli, C., Felger, I., Galinski, M.R., Mueller, I., Naturally acquired immune responses to P. vivax merozoite surface protein 3alpha and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl. Trop. Dis., 7, 2013, e2498.
92. Terheggen, U., Drew, D.R., Hodder, A.N., Cross, N.J., Mugyenyi, C.K., Barry, A.E., Anders, R.F., Dutta, S., Osier, F.H., Elliott, S.R., Senn, N., Stanisic, D.I., Marsh, K., Siba, P.M., Mueller, I., Richards, J.S., Beeson, J.G., Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Med., 12, 2014, 183.
93. Tran, T.M., Oliveira-Ferreira, J., Moreno, A., Santos, F., Yazdani, S.S., Chitnis, C.E., Altman, J.D., Meyer, E.V., Barnwell, J.W., Galinski, M.R., Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population. Am. J. Trop. Med. Hyg. 73 (2005), 244–255.
94. Tsuboi, T., Takeo, S., Arumugam, T.U., Otsuki, H., Torii, M., The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery. Acta Trop. 114 (2010), 171–176.
95. VanBuskirk, K.M., Cole-Tobian, J.L., Baisor, M., Sevova, E.S., Bockarie, M., King, C.L., Adams, J.H., Antigenic drift in the ligand domain of Plasmodium vivax Duffy binding protein confers resistance to inhibitory antibodies. J. Infect. Dis. 190 (2004), 1556–1562.
96. Versiani, F.G., Almeida, M.E., Melo, G.C., Versiani, F.O., Orlandi, P.P., Mariuba, L.A., Soares, L.A., Souza, L.P., da Silva Balieiro, A.A., Monteiro, W.M., Costa, F.T., del Portillo, H.A., Lacerda, M.V., Nogueira, P.A., High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms. Malar. J., 12, 2013, 294.
97. Vicentin, E.C., Francoso, K.S., Rocha, M.V., Iourtov, D., Dos Santos, F.L., Kubrusly, F.S., Sakauchi, M.A., Raw, I., Nosten, F., Renia, L., Rodrigues, M.M., Russell, B., Soares, I.S., Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect. Immun. 82 (2014), 1296–1307.
98. Wright, K.E., Hjerrild, K.A., Bartlett, J., Douglas, A.D., Jin, J., Brown, R.E., Illingworth, J.J., Ashfield, R., Clemmensen, S.B., de Jongh, W.A., Draper, S.J., Higgins, M.K., Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515 (2014), 427–430.
99. Wu, Y., Ellis, R.D., Shaffer, D., Fontes, E., Malkin, E.M., Mahanty, S., Fay, M.P., Narum, D., Rausch, K., Miles, A.P., Aebig, J., Orcutt, A., Muratova, O., Song, G., Lambert, L., Zhu, D., Miura, K., Long, C., Saul, A., Miller, L.H., Durbin, A.P., Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One, 3, 2008, e2636.
100. Zenonos, Z.A., Rayner, J.C., Wright, G.J., Towards a comprehensive Plasmodium falciparum merozoite cell surface and secreted recombinant protein library. Malar. J., 13, 2014, 93.
101. Zhou, J., Feng, G., Beeson, J., Hogarth, P.M., Rogerson, S.J., Yan, Y., Jaworowski, A., CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Med., 13, 2015, 154.
102. Zimmerman, P.A., Ferreira, M.U., Howes, R.E., Mercereau-Puijalon, O., Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv. Parasitol. 81 (2013), 27–76.